Kabra Drugs Ltd

📈 Kabra Drugs Q3 FY26: Revenue Jumps to ₹3,042 Lakhs, Returns to Profit

• Q3 FY26 revenue from operations: ₹3,042 lakhs

• Nine months total income (ended Dec 31, 2025): ₹5,771.32 lakhs

• Q3 FY26 net profit: ₹256.65 lakhs vs losses in Q1 FY25 (₹49.98 lakhs loss) and Q3 FY24 (₹53.69 lakhs loss)

• Nine months net profit: ₹390.34 lakhs vs ₹147.85 lakhs loss same period last year

• Earnings per share: ₹1.08 for Q3 FY26, ₹1.65 for nine-month period